Public Health Emergency Preparedness
This resource was part of AHRQ's Public Health Emergency Preparedness program, which was discontinued on June 30, 2011, in a realignment of Federal efforts.
This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
Table 6.9. Threshold Radioactive Exposures and Recommended Prophylactic Single Doses of KI
| Patients by Age/Sex |
Predicted Thyroid
Exposure (Gy) |
KI Dose (mg) |
No. of 130-mg
tablets |
No. of 65-mg
tablets |
Adults
>40 yr old |
≥5 |
130 |
1 |
2 |
Adults
18-40 yr |
≥0.1 |
130 |
1 |
2 |
| Pregnant or lactating women |
≥0.05 |
130 |
1 |
2 |
| Adolescents 12-18 yr old |
≥0.05 |
130 |
1 |
2 |
Children
3-12 yr old |
≥0.05 |
>65 |
1/2 |
1 |
Children
1 mo to 3 yr old |
≥0.05 |
32 |
1/4 |
1/2 |
Neonates
birth to 1 mo old |
≥0.05 |
16 |
1/8 |
1/4 |
Source: Adapted from U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research. Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies. Available at http://www.fda.gov/cder/guidance/4825fnl.htm.
Return to Document
5600 Fishers Lane Rockville, MD 20857